We use cookies for a better user experience. Read our Privacy Policy

I Agree

Parenteral Medication of Spasticity Treatment Market

Parenteral Medication of Spasticity Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020–2030

Parenteral Medication of Spasticity Treatment: Introduction

  •  Spasticity is a condition in which muscles stiffen or tighten, preventing normal fluid movement. The muscles remain contracted and resist being stretched, thus affecting movement, speech, and gait.
  • Spasticity is generally caused by damage or disruption to the areas of the brain and spinal cord that are responsible for controlling muscle and stretch reflexes. These disruptions can be due to an imbalance in the inhibitory and excitatory signals sent to the muscles, causing them to lock in place.
  • Parenteral treatment for spasticity includes botulinum toxin injection and phenol/alcohol injection. More effective methods of treatment for spasticity have still not been well-developed.

Key Drivers of Global Parenteral Medication of Spasticity Treatment Market

  • Increase in number of patients of spasticity associated with multiple sclerosis and spinal cord injury is anticipated to fuel the demand for therapeutics and consequently, drive the spasticity treatment market during the forecast period. According The National Center for Biotechnology Information, spasticity affects more than 12 million people worldwide. More than 500,000 people in the U.S. are estimated to suffer from upper limb spasticity.
  • According to National Multiple Sclerosis Society, nearly 1 million people in the U.S. are living with multiple sclerosis, and spasticity occurs in up to 84% of multiple sclerosis patients.
  • Data suggest that about 65% to 78% of the SCI population have some amount of spasticity, and it is more common in cervical (neck) than thoracic (chest) and lumbar (lower back) injuries
  • Ongoing clinical trials for spasticity treatment, drugs, pipeline products, and safety and efficacy studies have increased in the last few years. For instance, Revance Therapeutics, Inc. has an innovative product, i.e. Daxibotulinumtoxin A, for Injection in phase II for the treatment of upper limb spasticity.

Botulinum Toxin Injection Segment to be Highly Promising

  • Based on product type, the global parenteral medication of spasticity treatment market can be segmented into botulinum toxin injection and phenol/alcohol injection. The botulinum toxin injection segment can be further classified into Botox, Myobloc, Dysport, and others.
  • The botulinum toxin injection segment accounted for a prominent share of the global parenteral medication of spasticity treatment market in 2019. This segment is expected to dominate the parenteral medication of spasticity treatment market due to an increase in use of Botox, Myobloc, and Dysport in the treatment of spasticity.
  • Botulinum toxin products, such as Botox, are known to create an 88% improvement in stance, 77% improved gait speed, 88% improved joint positions. Additionally, strong botulinum toxin product pipeline is likely to drive the segment during the forecast period.

Hospital Pharmacies to be Most Promising Segment

  • In terms of distribution channel, the global parenteral medication of spasticity treatment market can be divided into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies was a prominent segment, in terms of revenue, in 2019. It is anticipated to expand significantly during the forecast period.
  • Expansion of healthcare infrastructure and increase in availability of all treatment options at one place are anticipated to boost the hospital pharmacies segment
  • Increase in number of patients with spasticity associated multiple sclerosis and spinal cord injury who require hospital visits fuels the hospital pharmacies segment

North America to Dominate Global Parenteral Medication of Spasticity Treatment Market

  • In terms of region, the global parenteral medication of spasticity treatment market can be categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • North America dominated the global parenteral medication of spasticity treatment market in 2019. It is expected to maintain its leading position during the forecast period. Dominance of the region can be attributed to an increase in patients with multiple sclerosis and spinal cord injury. Spasticity is commonly witnessed in multiple sclerosis and spinal cord injury patients. According to National Spinal Cord Injury Statistical Center, around 288,000 persons suffer from spinal cord injury, this range varies from 247,000 to 358,000 persons.
  • The market in Asia Pacific is projected to expand at a significantly high growth rate during the forecast period, owing to an increase in prevalence of multiple sclerosis and spinal cord injury, and strokes in emerging countries such as India and China

Key Manufacturers Operating in Global Market

The global parenteral medication of spasticity treatment market was highly fragmented in 2019. Key manufacturers operating in the global market are:

  • Allergan plc
  • Revance Therapeutics, Inc.
  • Ipsen Pharma
  • GlaxoSmithKline plc
  •  Edge Pharma

Parenteral Medication of Spasticity Treatment Market: Research Scope

Parenteral Medication of Spasticity Treatment Market, by Product Type

  • Botulinum Toxin
    • Botox
    • Myobloc
    • Dysport
    • Others
  • Phenol Block

Parenteral Medication of Spasticity Treatment Market, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Interested in this report?
Get a FREE Brochure now!

Request Brochure

*Get Brochure (PDF) sent to your email within minutes

N/A

Transparency Market Research Plus

Get a free copy if the report you purchased is updated within 90 days

Copyright © Transparency Market Research, Inc. All Rights reserved